FDA Approves Tylenol with Naproxen, the First OTC Fixed-Dose Combination of Acetaminophen and Naproxen Sodium
核心洞察
The FDA has approved Tylenol with Naproxen, the first and only over-the-counter fixed-dose combination of 650 mg acetaminophen and 220 mg naproxen sodium for persistent pain relief.
Eight clinical studies demonstrated superior pain relief versus either ingredient alone, with onset in under 30 minutes and 12-hour duration from a single dose.
An estimated 75% of persistent pain sufferers report dissatisfaction with current options, and up to 1 in 4 patients prescribed opioids face addiction risk, highlighting the unmet need this product addresses.
SUMMIT, N.J., July 24, 2026 — Tylenol, the #1 doctor-recommended pain relief brand, today announced that the U.S. Food and Drug Administration (FDA) has approved Tylenol with Naproxen — the first and only over-the-counter (OTC) fixed-dose combination of acetaminophen and naproxen sodium. The approval marks a significant expansion of non-opioid options for persistent pain, combining 650 mg of acetaminophen with 220 mg of naproxen sodium in a single, clinically proven dose.
The new formulation begins working in under 30 minutes and provides 12 hours of pain relief, addressing what Kenvue (搜索) describes as a critical gap in persistent pain management. According to the Kenvue Pain Consumer Survey (March 2026, n=6,240), an estimated 75% of persistent pain sufferers report dissatisfaction with their current relief options. The U.S. Department of Labor further reports that up to 1 in 4 patients prescribed opioids are at risk of addiction.
"This milestone reflects the long-standing leadership of Tylenol in translating rigorous clinical science into accessible, over-the-counter solutions," said Dr. Rajesh Mishra, MD, PhD, Chief Medical Officer at Kenvue (搜索). "Persistent pain often leaves people trapped in a cycle of trial and error, navigating between choosing short-term relief or more complex treatment options. Tylenol with Naproxen simplifies that choice, offering fast onset, 12-hour duration, and the safety profile of two well-established non-opioid ingredients in one fixed-dose."
Robust Clinical Evidence Across Eight Studies
The FDA approval is supported by eight clinical studies in which the fixed-dose combination of 650 mg acetaminophen and 220 mg naproxen sodium consistently demonstrated superior pain relief versus acetaminophen alone and naproxen sodium (Aleve 220 mg) alone. Key findings from the clinical program include onset of relief in under 30 minutes and a duration of relief lasting 12 hours from a single dose.
"The clinical program behind Tylenol with Naproxen was designed to answer a practical question: could we deliver fast onset and sustained pain relief in a single, opioid-free OTC option, without asking patients to combine multiple products on their own?" said Todd Bertoch, MD, Chief Medical Officer, Pain Research at CenExel Clinical Research, Inc., and a principal investigator on the clinical program. "Across the eight clinical studies supporting the FDA approval, the 650 mg acetaminophen and 220 mg naproxen sodium fixed-dose combination consistently outperformed either ingredient alone. What makes this meaningful for clinicians is not just the efficacy; it's the rigor of the development program and the fact that patients can now access a clinically proven fixed-dose combination over-the-counter."
Clinical data demonstrating the efficacy and use of Tylenol with Naproxen across multiple pain models will be presented at upcoming medical congresses, including PAINWeek 2026.
Simplifying Multimodal Pain Management
For many patients, managing persistent pain has meant navigating a complex, multi-step approach involving multiple medications, staggered dosing schedules, or prescription options. Tylenol with Naproxen helps simplify pain management with a multimodal OTC option designed to support both adherence and relief, eliminating the need to time or coordinate multiple over-the-counter pain relievers.
The product combines two distinct mechanisms of action: acetaminophen is believed to work quickly to reduce pain signals, while naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID), provides longer-lasting relief by targeting pain caused by inflammation. The combination is opioid-free and carries no opioid risk.
Regulatory Exclusivity and Market Availability
The FDA has granted Tylenol a three-year period of exclusivity for this new OTC formulation, underscoring the significance of the innovation. Tylenol with Naproxen will be coming soon to major U.S. retailers nationwide.
The approval builds on more than 70 years of Tylenol leadership in acetaminophen science, safety, and stewardship. The brand's history includes introducing the first children's liquid acetaminophen product and helping to establish higher-dose OTC pain relief as a new category standard with the launch of 500 mg Extra Strength Tylenol.